Igene Biotechnology, Inc.
IGNE · OTC
9/30/2010 | 6/30/2010 | 3/31/2010 | 12/31/2009 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $5 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | -$36 |
| Gross Profit | $0 | $0 | $0 | $41 |
| % Margin | – | – | – | 850.3% |
| R&D Expenses | $528 | $513 | $470 | $530 |
| G&A Expenses | $62 | $79 | $73 | $194 |
| SG&A Expenses | $142 | $296 | $209 | $298 |
| Sales & Mktg Exp. | $80 | $216 | $136 | $104 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $95 | $127 | $148 | $268 |
| Operating Income | -$626 | -$822 | -$541 | -$343 |
| % Margin | – | – | – | -7,143.4% |
| Other Income/Exp. Net | $9 | $14 | $385 | $73 |
| Pre-Tax Income | -$617 | -$808 | $0 | $0 |
| Tax Expense | $532 | $685 | $401 | $159 |
| Net Income | -$627 | -$811 | -$549 | -$386 |
| % Margin | – | – | – | -8,043% |
| EPS | -0 | -0.001 | -0 | -0 |
| % Growth | 20% | -25% | -100% | – |
| EPS Diluted | -0 | -0.001 | -0 | -0 |
| Weighted Avg Shares Out | 1,565,404 | 1,565,404 | 1,562,727 | 1,550,258 |
| Weighted Avg Shares Out Dil | 1,565,404 | 1,565,404 | 1,562,727 | 1,550,258 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $10 | $3 | $8 | $43 |
| Depreciation & Amortization | $38 | $38 | $38 | $26 |
| EBITDA | -$58 | -$89 | -$110 | -$201 |
| % Margin | – | – | – | -4,187.1% |